[Non-response and change of anti-VEGF agent in exsudative age-related macular degeneration].
Manfreda
I
I
Klinik und Poliklinik für Augenheilkunde, Universitätsklinikum Münster.
Uhlig
C E
CE
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide / Q000008:administration & dosage*; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy*; D003131:Combined Modality Therapy; D005451:Fluorescein Angiography; D006801:Humans; D056965:Injections, Intraocular; D008297:Male; D010778:Photochemotherapy; D000069579:Ranibizumab; D012160:Retina / Q000187:drug effects; D019233:Retreatment; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014792:Visual Acuity; D014822:Vitreous Body; D057135:Wet Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; D042461:Vascular Endothelial Growth Factor A; C495058:pegaptanib; D000068258:Bevacizumab; D000069579:Ranibizumab